Breast cancer (BC) is a heterogeneous disease in which estrogen receptor (ER) expression
plays an important role in most tumors. A clinical dilemma may arise when a metastasis …

16α-18F-fluoro-17β-estradiol (18F-FES) is an estrogen receptor (ER)–specific PET tracer
with various potential interesting applications. The precise contribution of this technique in …

PURPOSE Determining the estrogen receptor (ER) status is essential in metastatic breast
cancer (MBC) management. Whole-body ER imaging with 16α-[18F] fluoro-17β-estradiol …

Objective To evaluate the clinical value of 16α-[18F] fluoroestradiol (18F-FES) PET/CT in
assisting the individualized treatment decisions of breast cancer patients. Methods Thirty …

The estrogen receptor (ER), a steroid hormone receptor important in female physiology, is a
significant contributor to breast carcinogenesis and progression and, as such, is an …

PET imaging with 16α-18F-fluoro-17β-fluoroestradiol (18F-FES), a radiolabeled form of
estradiol, allows whole-body, noninvasive evaluation of estrogen receptor (ER). 18F-FES is …

Purpose We compared the clinical value of 16a‐18F‐fluoro‐17b‐estradiol (18F‐FES)
positron emission tomography (PET)/computed tomography (CT) and 18F‐fluoro‐2‐deoxy …

Estrogen receptor (ER) status by immunohistochemistry (IHC) of cancer tissue is currently
used to direct endocrine therapy in breast cancer. Positron emission tomography (PET) with …

Correct staging is the most crucial for the treatment outcome in cancer management.
Molecular imaging with 18 F-fluoroestradiol (FES) positron emission tomography-computed …

Abstract Introduction [18F] Fluoroestradiol ([18F] FES) PET/CT has been proposed as a tool
for detecting the oestrogen receptor density in patients with metastatic breast cancer (BC) …